Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

In a prospective cohort of 1,127 patients with non-small cell lung cancer and ctDNA-guided therapy, ctDNA detection was associated with shorter survival, independently of clinicopathologic features. NSCLC LungCancer LCAM22 MSKCancerCenter

J.J. has a patent licensed by MDSeq. A.N. reports serving as a one-time paid consultant for Bayer. P.K.P.

has served on advisory boards or received personal honoraria from Boehringer Ingelheim, MSD, Merck, Bristol-Myers Squib, Astra Zeneca, Takeda, Pfizer, Roche, Novartis, Ipsen and Bayer and has received research funding to his institution from Bayer, Pfizer and Roche. A.L. reports personal fees and travel funding from Mundipharma/Helsinn, personal fees from Bayer and personal fees from Eisai. G.J.R.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

MSKCancerCenter It’s lung cancer awareness month and I have lung cancer now I’m wheezing short of breath and you can’t get me in for a ct scan till end of November? That’s a disgrace. Been with you three years I deserve better

MSKCancerCenter MSK is the worst place on earth! My beautiful 37 year old daughter died from horrible doctors she had ! Septic shock right in hospital doctors did nothing to stop it!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Spatial genomics maps the structure, nature and evolution of cancer clones - NatureA workflow centred around base-specific in situ sequencing generates detailed maps of, and can phenotypically characterize, the unique set of subclones of cancers. Researchers develop a new method to map the spatial evolution of cancers Portfolio emblebi sangerinstitute cancer oncology genetics evolution
Source: Nature - 🏆 64. / 68 Read more »